longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

ANKE BIO

300009

8.080.75% ( +0.06 )
Delay Closed: Sep 17, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 19.26, within the reasonable range, cheaper than 65.9% of the time in the past 3 years, and the industry ranks 5/85, the industry Median 11.73.

19.26xP/E
¥8.08Stock price
¥0.42Earnings per share
19.26xP/E
Stock price¥8.08Earnings per share¥0.42

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
20.03x
Typical range
18.51x–23.97x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 11.73x
03978117156

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 11.73x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
688331SHRemeGen
11.07x486.37%¥64.42B
688336SHSunshine Guojian Pharmaceutical
11.73x78.00%¥36.14B
688278SHAMOYTOP
18.88x19.44%¥20.39B
300009SZANKE BIO
19.26x6.82%¥13.50B
300685SZAmoyDx
19.96x10.37%¥6.75B
603387SHGetein Biotech
16.23x--¥4.81B
688136SHSDKX
19.40x21.52%¥4.06B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.